Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

A study reveals real-world outcomes of neoadjuvant immune checkpoint inhibitors in nonmetastatic colon cancer, highlighting ...

The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear.

Use of neoadjuvant or perioperative immunotherapy in combination with chemotherapy has proven effective for some patients ...

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's ...

Older adults tolerate neoadjuvant chemoradiation for oesophageal cancer well, with survival outcomes comparable to younger ...

MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

The incidence of early-onset pancreatic cancer (EOPC) is rising, yet optimal treatment strategies remain unclear. While adjuvant chemotherapy (ACT) has shown survival benefits in pancreatic ductal ...

Pathologic complete response does not predict overall or disease-free survival in patients with rectal cancer, according to a ...

CHICAGO — Neoadjuvant FOLFIRINOX chemotherapy failed to extend OS compared with upfront surgery for patients with resectable pancreatic head cancer, according to study results presented at ASCO ...

The NeoAdjuvant Lapatinib and/or Trastuzumab Optimization (NeoALTTO) trial was a three-armed study addressing the comparative efficacy of single compared with dual HER2 blockade using trastuzumab (4 ...